Paradromics Cleared to Start Connexus Long-Term Clinical Speech Trial

Abstract

The FDA approved Paradromics' first long-term clinical trial of its Connexus brain-computer interface implant in November 2025, with the trial proceeding through 2026. The trial aims to safely restore speech for people with severe motor impairments, with primary endpoints around device safety and the ability to communicate in real-time speech. Paradromics claims Connexus achieves >200 bits-per-second information transfer rate — by their measure, >20× Neuralink N1 and orders of magnitude beyond Synchron Stentrode endovascular systems.

Key Contributions

• First long-term clinical trial approval — moves Paradromics from preclinical to in-human evaluation.
• >200 bps information transfer rate disclosed — sets a new high-water mark for invasive BCI bandwidth.
• Speech restoration target: directly competes with Stanford inner-speech decoding research and Synchron's communication-focused trials.
• Establishes three-way invasive BCI clinical race: Neuralink (Telepathy / Blindsight), Synchron (Stentrode), Paradromics (Connexus).

Methodology / Trial Design

• Long-term implant in patients with severe motor impairment.
• Primary safety endpoints over multi-month follow-up.
• Functional speech-restoration milestones.
• Cohort size and timeline specifics in trial registration.

Results

• Trial in progress as of April 2026.
• Pre-clinical Connexus reports demonstrate >200 bps info transfer rate.
• Paradromics emerging as a third credible invasive-BCI clinical program in the US.

Limitations

• Bandwidth claims are pre-clinical; clinical demonstration pending trial completion.
• Long-term biostability of Connexus electrodes (>2-year horizon) is the standing question for all intracortical implants.
• Patient cohort is necessarily small in safety-focused initial trials.

Full Content

The Paradromics Connexus advance reframes the invasive-BCI competitive landscape. From 2024-2025, the public conversation was dominated by Neuralink (Telepathy + Blindsight) and Synchron (less-invasive Stentrode positioned as the clinical pragmatic option). Paradromics enters with a higher-bandwidth intracortical approach — explicitly targeting the bandwidth ceiling that limits Neuralink-style implants.

The 200 bps figure matters because the binding constraint on speech BCIs is information rate. Stanford's high-performance speech neuroprosthesis demonstrated 62-78 words per minute with 9-25% word error rates on intracortical microelectrode arrays. Paradromics' >200 bps would correspond to faster, more accurate decoding if validated in clinical trials.

For 2026-2027, watch:

• Trial results from Paradromics (cohort safety, decoding performance)
• Neuralink's pace of cohort expansion (P1, P2, P3 patient updates)
• Synchron's 50+ patient cohort outcomes — endovascular's lower bandwidth vs higher safety
• FDA regulatory framework evolution for long-term BCI implants (see Statnews coverage of regulatory hurdles)
• Whether "200 bps" generalizes outside Paradromics-specific testing protocols

Source: pharmaphorum — Neuralink rival Paradromics cleared to start speech trial, companion Nature coverage d41586-025-03849-0